OUR SCIENCE
A new generation of therapies

We apply scientific innovation and clinical intelligence to advance a new generation of differentiated therapies to better address unmet needs for patients with immunologic and inflammatory diseases.
woman smiling - our science hero

miragene pipeline

ASSET
TARGET
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
MAG-007

BTK
(3rd-gen BTKi with once-daily potential)

Chronic spontaneous urticaria
Other indications to be disclosed

PRECLINICAL
PHASE 1
PHASE 2
MAG-017

BDCA2
(pDC depleting mAb)

Cutaneous lupus erythematousus
Systemic lupus erythematousus

PRECLINICAL
PHASE 1
PHASE 2
MAG-024

Two targets to be disclosed
(bi-specific mAb with extended half-life)

To be disclosed

PRECLINICAL
PHASE 1
PHASE 2

led by Partners

ASSET
TARGET
INDICATION
PRECLINICAL
PHASE 1
MAG-018*

ILT7
(mAb)

To be disclosed

PRECLINICAL
PHASE 1
MAG-013+

IL7Ra
(mAb)

To be disclosed

PRECLINICAL
PHASE 1

*Formed partnership with Aditum Bio to create Celexor Bio
+Global rights out-licensed to Ornovi Inc.

MAG-007 - highly selective noncovalent reversible BTK inhibitor - MOA

MAG-007

a potent, highly selective, noncovalent, reversible BTK inhibitor

MAG-007 is a noncovalent, reversible, and highly selective oral inhibitor of Bruton’s tyrosine kinase (BTK), specifically designed for the treatment of inflammatory and autoimmune diseases that often require long-term therapy. It is brain-permeable and exhibits potent activity. In Phase 1 studies in healthy adults, MAG-007 demonstrated a favorable safety profile, extended half-life, and durable pharmacodynamic effects—supporting the potential for once-daily (QD) dosing. The program is now ready to advance into Phase 2 development.

MAG-017

A pDC depleting anti-BDCA2 mAb

MAG-017, a plasmacytoid dendritic cell (pDC)–depleting anti-BDCA2 monoclonal antibody, has the potential to provide clinical benefit across multiple inflammatory and autoimmune diseases, including lupus. Currently in preclinical development, MAG-017 combines two complementary mechanisms relevant to lupus pathogenesis: BDCA2-mediated inhibition of type I interferon (IFN-I) signaling and direct depletion of pDCs, the major cellular source of IFN-I. In preclinical studies, MAG-017 has demonstrated greater potency in suppressing IFN-I production and in eliminating pDCs compared with leading competitive molecules.

微信图片_20251114122521.png

QuadraTek®:

a platform for innovation

Our proprietary QuadraTek® platform is designed to create highly differentiated biologic drug candidates with the potential to better address unmet needs in immunologic and inflammatory diseases.

Four parallel systems to generate diversified, high-performing leads

Proprietary functional assays to select competitive, differentiated drug candidates

Advanced protein engineering to optimize different aspects of a product



Scroll to Top